Prescriptions for Merck's (MRK) and Schering-Plough's (SGP) embattled cholesterol drug Vytorin drop sharply in two weeks since study raised questions about effectiveness. Companies stand behind drug in reducing bad cholesterol.
Both stocks are down over 20% since the study was first announced....
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment